Lavipharm

Lavipharm Receivables

The Accounts Receivable of Lavipharm (LAVI.AT) as of Nov 3, 2026 is 15.61 M EUR. In the previous year, Accounts Receivable was 18.53 M EUR — a change of -15.76% (lower).

Receivables

15.61 MEUR

YoY

-15.76%

Last updated:

Accounts Receivable of Lavipharm is 2024 15.61 M EUR. Accounts Receivable of Lavipharm was 2023 18.53 M EUR. It decreases by -15.76% lower compared to the previous year.

The Lavipharm Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2023
18.53 M EUR
Jan 1, 2024
15.61 M EUR
The Lavipharm Receivables history
YEARReceivablesYoY
15.61 MEUR-15.76%
18.53 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Accounts Receivable of Lavipharm is 15.61 M EUR in 2024.

Accounts Receivable of Lavipharm changed from 18.53 M EUR to 15.61 M EUR, representing a -15.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Lavipharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lavipharm

All Key Metrics — Lavipharm